Comparative Pharmacology
Head-to-head clinical analysis: ATROPINE AND DEMEROL versus PROPOXYPHENE HYDROCHLORIDE AND ACETAMINOPHEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ATROPINE AND DEMEROL versus PROPOXYPHENE HYDROCHLORIDE AND ACETAMINOPHEN.
ATROPINE AND DEMEROL vs PROPOXYPHENE HYDROCHLORIDE AND ACETAMINOPHEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Atropine is an antimuscarinic agent that competitively blocks acetylcholine at muscarinic receptors, reducing secretions and gastrointestinal motility. Meperidine (Demerol) is an opioid agonist that binds to mu-opioid receptors in the CNS, altering pain perception and producing analgesia.
Propoxyphene is a mu-opioid receptor agonist; acetaminophen inhibits cyclooxygenase (COX) and modulates central pain pathways.
Atropine 0.4 mg and Demerol (meperidine) 50-100 mg intramuscularly as preanesthetic medication 30-60 minutes before procedure.
One tablet (propoxyphene HCl 65 mg/acetaminophen 650 mg) orally every 4 hours as needed for pain; maximum: 6 tablets per day.
None Documented
None Documented
Atropine: 2-4 hours (terminal half-life). Demerol: 2.5-4 hours; normeperidine metabolite half-life 15-30 hours (accumulates in renal impairment).
Propoxyphene: 6-12 h (prolonged in hepatic disease); Norpropoxyphene (active metabolite): 30-36 h (accumulation risk). Acetaminophen: 2-3 h (prolonged in hepatic disease).
Atropine: approximately 50% excreted unchanged in urine, remainder as metabolites (biliary and renal). Demerol (meperidine): primarily hepatic metabolism; <5% excreted unchanged in urine; metabolites (including normeperidine) excreted renally.
Renal: Propoxyphene ~20-25% as unchanged drug and metabolites; Acetaminophen ~85-90% as glucuronide and sulfate conjugates, <5% unchanged. Fecal: Minimal for both.
Category C
Category C
Opioid Analgesic Combination
Opioid Analgesic Combination